Table 2

Meta-analysis summary statistics for the most significantly associated variants with maximal site of JSN and with bone remodelling response phenotypes of hip OA

Study characteristics			SNP characteristics						Meta-analysis		Sex-adjusted meta-analysis
Cases definition	Controls definition	N case/control	SNP	Chr	Position (b37)	Nearest gene(s)	EA	EAF case/control	OR (95% CI)	p Value	OR (95% CI)	p Value
Hip OA with superior JSN	Hip OA with non-superior JSN	1469/649	rs754106	13	47 152 655	LRCH1	T	0.51/0.60	0.70 (0.61 to 0.80)	1.49×10⁻⁷	0.72 (0.62 to 0.82)	2.17×10⁻⁶
Hip OA with axial/medial JSN	Hip OA with non-axial/medial JSN	501/1617	rs754106	13	47 152 655	LRCH1	T	0.61/0.52	1.47 (1.27 to 1.70)	3.66×10⁻⁷	1.42 (1.22 to 1.65)	6.92×10⁻⁶
Hip OA with superior JSN	Hip OA with non-superior JSN	1469/649	rs73023563	2	181 502 830	CWC22 UBE2E3	T	0.21/0.14	1.59 (1.33 to 1.91)	6.59×10⁻⁷	1.58 (1.31 to 1.90)	1.65×10⁻⁶
Hip OA with axial/medial JSN	Hip OA with non-axial/medial JSN	501/1617	rs73023563	2	181 502 830	CWC22 UBE2E3	T	0.14/0.20	0.61 (0.50 to 0.75)	2.03×10⁻⁶	0.62 (0.50 to 0.76)	5.44×10⁻⁶
Hip OA with axial/medial JSN	Hip OA with non-axial/medial JSN	501/1617	rs17050727	4	121 426 827	PRDM5	T	0.18/0.12	1.65 (1.35 to 2.01)	6.87×10⁻⁷	1.67 (1.36 to 2.05)	8.38×10⁻⁷
Hip OA with hypertrophic response	Hip OA with non-hypertrophic response	637/1481	rs6766414	3	31 488 222	STT3B GADL1	G	0.29/0.22	1.45 (1.24 to 1.69)	3.13×10⁻⁶	1.46 (1.25 to 1.70)	2.31×10⁻⁶
Hip OA with hypertrophic response	Hip OA with non-hypertrophic response	637/1481	rs61837881	1	223 626 562	CAPN8 C1orf65	C	0.29/0.22	1.44 (1.23 to 1.68)	4.56×10⁻⁶	1.43 (1.23 to 1.67)	5.55×10⁻⁶

EA, effect allele; EAF, effect allele frequency; JSN, joint space narrowing; OA, osteoarthritis; SNP, single nucleotide polymorphism.